Home » Prescription Drugs 9 » Intalith CR Eskalith
Indications1.Treatment of mania and hypomania. 2.Lithium may also be tried in the treatment of some patients with recurrent bipolar depression for which treatment with other antidepressants has been unsuccessful. 3.Prophylactic treatment of recurrent affective disorders.Dosage and AdministrationA simple treatment schedule has been evolved which except for some minor variations should be followed whether using LITHICARB FC therapeutically or prophylactically. The minor variations to this schedule depend on the elements of the illness being treated and these are described later.1. In patients of average weight (70kg) an initial dose of 400- 1 200mg of LITHICARB FC may be given as a single daily dose in the morning or on retiring. Alternatively the dose may be divided and given morning and evening. The tablets should not be crushed chewed or swallowed with hot liquids. When changing from other lithium preparations serum lithium levels should first be checked then 2. LITHICARB FC therapy commenced at a daily dose as close as possible to the dose of the other form of lithium. As bioavailability varies from product to product (particularly with regard to retard or slow release preparations) a change of product should be regarded as initiation of new treatment. 3. Four to five days after starting treatment (and never longer than one week) a blood sample should be taken for the estimation of serum lithium level. 4. The objective is to adjust the LITHICARB FC dose so as to maintain the serum lithium level permanently within the diurnal range of 0.5 - 1.5 mmol/L. In practice the blood sample should be taken between 12 and 24 hours after the previous dose of LITHICARB FC. 'Target' serum lithium concentrations at 12 and 24 hours are shown in Table 1.LITHICARB FC tablets are scored therefore they can be divided accurately to provide dosage adjustments as small as 125mg. Serum lithium levels should be monitored weekly until stabilisation is achieved.Table 1. Target serum lithium concentrations "Target" serum lithium concentration (mmol/L) At 12 hours At 24 hours Once daily dosage 0.7 - 1.0 0.5 - 0.8 Twice daily dosage 0.5 - 0.8 4. Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available. Following stabilisation of serum lithium levels the period between subsequent estimations can be increased gradually but should not normally exceed three months. Additional measurements should be made following alteration of dosage on development of intercurrent disease signs of manic or depressive relapse following significant change in sodium or fluid intake or if signs of lithium toxicity occur. 5. Whilst a high proportion of acutely ill patients may respond within three to seven days of the commencement of LITHICARB FC therapy LITHICARB FC should be continued through any recurrence of the affective disturbance. This is important as the full prophylactic effect may not occur for 6 to 12 months after the initiation of therapy. 6. In patients who show a positive response to LITHICARB FC therapy treatment is likely to be long term. Careful clinical appraisal of the patient should be exercised throughout medication (see Precautions).Treatment of Acute Mania Hypomania and Recurrent Bipolar Depression:It is likely that a higher than normal LITHICARB FC intake may be necessary during an acute phase and divided doses would be required here. Therefore as soon as control of mania or depression is achieved the serum lithium level should be determined and it may be necessary dependent on the results to lower the dose of LITHICARB FC and re-stabilise serum lithium levels. In all other details the described treatment schedule is recommended.Prophylactic Treatment of Recurrent Affective DisordersIt is recommended that the described treatment schedule is followed.Use in the Elderly:In elderly patients or those below 50kg in weight it is recommended that the starting dose be 400mg. Elderly patients may be more sensitive to undesirable effects of lithium and may also require lower doses in order to maintain normal serum lithium levels. It follows therefore that long term patients often require a reduction in dosage over a period of years.Use in Children and AdolescentsNot recommended.
Buy Intalith CR Eskalith and other Prescription Drugs 9 products online
at Medstore.
789 Buy Online at Medstore - Click Here!

About Intalith CR Eskalith:
Product Type: Prescription Drugs 9
Intalith CR (Eskalith Generic Lithium Carbonate)
Intalith CR (Eskalith Generic Lithium Carbonate)
Eskalith Generic Lithium Carbonate
450mg 400(4 x 100) Tablets 200(2 x 100) Tablets 100 Tablets
Eskalith Generic Lithium Carbonate Intalith CR

View more
Prescription Drugs 9
Previous Product Next Product
Direct Pharmacy:
About Medstore Discount Drugs Pharmacy: Frequently Asked Questions Where are you located? We have shipping facilities in the South Pacific, Europe and the Asia. The shipping address depends on the product you have ordered and from which manufacturer or wholesaler it is being supplied from.
News: Micronutrient powder helps prevent malnutrition in children up to two years old, study review shows
In a systematic review published by the Cochrane Collaboration last week, researchers found that the micronutrient powder used in recent years to combat malnutrition, anemia and iron deficiency in children was very helpful in preventing malnutrition in children six to 24 months old, VOA News reports. WHO epidemiologist Luz Maria De Regil "and other researchers combined the results of eight previous studies involving thousands of children," VOA writes, adding, "The studies were done on three continents, in countries as varied as Haiti, Cambodia and Ghana."
"Specifically, the supplement powder reduced anemia by about one-third and iron deficiency by half compared to no supplement or a placebo," VOA notes. "The micronutrient powder seems to be about equally effective as iron supplements, but the authors say that conclusion should be treated 'cautiously,' because of limited data," the news service adds (Chimes, 9/9).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
ZAART H Hyzaar
Zanaflex (Tizanidine)
Zantac Generic Ranitidine
Zantac (Ranitidine)
Zarontin Generic Ethosuximide
Zarontin Syrup Generic Ethosuximide
Zebeta (Bisoprolol)
Zeffix Generic Imaivudine
Zelnorm (Tegaserod)
Zerit (Stavudine)
Zero Nicotine
Zestoretic (Lisinopril + Hydrochlorothiazide)
Zestril (Lisinopril)
Zestril Prinivil
Zetia (Ezetimibe)
ZIDOVIR 300 AZT
ZIDOVIR AZT
Ziprax Suprax
Zipsydon Geodon
Zithromax Generic Azithromycin
Zithromax (Azithromycin)
Zitrotek Zithromax
ZOBID D Voltaren
Zocon Diflucan
Zocor
Zocor Forte Lipex
Zocor (Simcard)
ZOFLUT Generic Fluticasone
Zofran Generic Ondansetron
Zofran (Ondansetron)
Zoladex Generic Goserelin
Zoloft Lustral
Zomig Generic Zolmitriptan
ZONISEP Zonegran
Zoton Prevacid


|